Overall survival from the phase III postMONARCH trial of abemaciclib plus fulvestrant versus placebo plus fulvestrant for HR-positive, HER2-negative advanced breast cancer following progression on a prior CDK4/6 inhibitor plus endocrine therapy☆

Annals of Oncology · Elsevier

Аннотация

Publication date: Available online 24 October 2026 Source: Annals of Oncology Author(s): K. Kalinsky, S.A. Wander, E. Hamilton, S.L. Graff, R. Jeselsohn, K.H. Park, U. Demirci, M. Martin, R.M. Layman, S.A. Hurvitz, S. Sammons, P.A. Kaufman, E. Ravenberg, S. Amdur, L.M. Litchfield, G. Bianchini

Читать у издателя →

Похожие статьи